MicroRNA-125b as a Preeclampsia Biomarker

Abstract

Pregnancy hypertensive disorder (PHD) is a broad term referring to conditions related to disorders of high blood pressure during pregnancy. Preeclampsia is one of 4 types of PHD characterized by an increase in systolic blood pressure ≤ 140 mmHg with a diastolic pressure ≤ 90 mmHg accompanied by proteinuria of 1+ or more. Complications of PHD include peripartum cardiomyopathy, maternal mortality, pulmonary edema, cerebrovascular accident and renal failure. As consequence, early detection of PHD is crucial in preventing complications. “Preeclampsia”, “microRNA-125b” and “Biomarker” were the keywords applied to scientific online databases, such as ScienceDirect, PubMed, and Researchgate. A total of 46 journals were screened, reviewed and utilized with utmost precision to construct this literature review. Looking at the dangers of preeclampsia on infants and mothers, miRNA-125b has potential to be used as a biomarker of preeclampsia that can occur in the third trimester. The increase in the concentration of miRNA-125b in the first trimester causes inhibition of trophoblast invasion, which is followed by inhibition of KCNA1, GPC1, and SGPL1. All of these proteins play a role in the invasion trophoblast which is also exacerbated by the increase in the concentration of mir-125b. All in all, these symptoms and the increase of mir-125b that appear in the first trimester yield as a promising result as biomarkers of preeclampsia in the third trimester. Keywords: preeclampsia, microRNA-125b, biomarker, SGPL1, maternal, infants.